<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2837">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01474317</url>
  </required_header>
  <id_info>
    <org_study_id>CTD-PRO-2010-009-01</org_study_id>
    <nct_id>NCT01474317</nct_id>
  </id_info>
  <brief_title>Study of an Investigational Glucose Meter System</brief_title>
  <official_title>Performance of the G3 Blood Glucose Monitoring System With TATSU Strip</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ascensia Diabetes Care</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ascensia Diabetes Care</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that untrained subjects who have diabetes can
      operate the Investigational Blood Glucose Monitoring System (BGMS) and obtain valid glucose
      results.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">November 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (&lt;100mg/dL) or Within +/- 5to15% (&gt;=100mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI Analyzer BG results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 5to15% (&gt;=100mg/dL YSI capillary plasma). Site staff tested in parallel after subjects.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Untrained subjects with diabetes self-test Alternative Site (AST) Palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma BG results are used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of Venous Blood Glucose Results Within +/- 5to15mg/dL (&lt;75mg/dL) or Within +/- 5to20% (&gt;=75mg/dL) of Laboratory Glucose Method</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>Study staff tested subject venous blood using an investigational Blood Glucose Monitoring System (BGMS). Venous BGMS results are compared with venous plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI venous plasma results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;75mg/dL YSI venous plasma) or +/- 5to20% (&gt;=75mg/dL YSI venous plasma).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction</measure>
    <time_frame>1 hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>After reading the instructions for use, and without assistance from the study staff, subjects use the BGMS to utilize some of the additional features of the system. Study staff documents Yes or No 'Did the subject complete the task successfully?'</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">226</enrollment>
  <condition>Diabetes</condition>
  <arm_group>
    <arm_group_label>Intended Users of the Monitoring System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>G3 Investigational Blood Glucose Monitoring System</intervention_name>
    <description>Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
    <arm_group_label>Intended Users of the Monitoring System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and females, 18 years of age and older

          -  Type 1 or type 2 diabetes

          -  Able to speak, read, and understand English

          -  Willing to complete all study procedures

        Exclusion Criteria:

          -  Pregnancy

          -  Hemophilia or any other bleeding disorder

          -  Previously participated in a study using the G3 system

          -  Working for a medical laboratory, hospital or other clinical setting that involves
             training on and clinical use of blood glucose monitors.

          -  A condition, which in the opinion of the investigator, would put the person or study
             conduct at risk (reason for exclusion will be clearly documented by investigator or
             designee).

          -  Working for a competitive medical device company, or having an immediate family
             member or someone who is not a family member but is living within the household of
             someone who works for such a company.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Bernstein, MD, FACE</last_name>
    <role>Principal Investigator</role>
    <affiliation>Southwest Clinical Research Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Caswell, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Consumer Product Testing Co.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Consumer Product Testing Co.</name>
      <address>
        <city>Fairfield</city>
        <state>New Jersey</state>
        <zip>07004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Clinical Research Center</name>
      <address>
        <city>Santa Fe</city>
        <state>New Mexico</state>
        <zip>87505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <lastchanged_date>January 29, 2016</lastchanged_date>
  <firstreceived_date>November 16, 2011</firstreceived_date>
  <firstreceived_results_date>November 30, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system.
G3 Investigational Blood Glucose Monitoring System : Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="226"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="224"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject ineligible for study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intended Users of the Monitoring System</title>
          <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system. Of 226 subjects enrolled, 224 completed the study
G3 Investigational Blood Glucose Monitoring System : Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="224"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <description>224 subjects completed the study</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="54.4" lower_limit="23" upper_limit="78"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="131"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="93"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="224"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (&lt;100mg/dL) or Within +/- 5to15% (&gt;=100mg/dL) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI Analyzer BG results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 5to15% (&gt;=100mg/dL YSI capillary plasma). Site staff tested in parallel after subjects.</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <population>Blood data for three subjects were not evaluable because time defined in protocol was exceeded between meter test and blood sample preparation for reference method. 221 (224-3) blood test results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the G3 Investigational BG Monitoring System</title>
            <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system. Of 226 subjects enrolled, 224 completed the study.
G3 Investigational Blood Glucose Monitoring System : Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Self-Test Fingerstick Blood Glucose Results Within +/- 5to15mg/dL (&lt;100mg/dL) or Within +/- 5to15% (&gt;=100mg/dL) of Laboratory Glucose Method</title>
            <description>Untrained subjects with diabetes self-test fingerstick blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI Analyzer BG results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;100mg/dL YSI capillary plasma) or +/- 5to15% (&gt;=100mg/dL YSI capillary plasma). Site staff tested in parallel after subjects.</description>
            <units>percentage of meter test results</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>% within 15 mg/dL(&lt;100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 15% (&gt;=100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 12.5 mg/dL (&lt;100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 12.5% (&gt;=100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10 mg/dL (&lt;100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10% (&gt;=100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="95.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5 mg/dL (&lt;100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="76.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5% (&gt;=100 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="78.6"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
        <description>Untrained subjects with diabetes self-test Alternative Site (AST) Palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma BG results are used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma).</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <population>Blood data for 3 subjects were not evaluable because time defined in protocol was exceeded between meter test and blood sample preparation for reference method. 221 (224-3) blood test results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the G3 Investigational BG Monitoring System</title>
            <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system. Of 226 subjects enrolled, 224 completed the study.
G3 Investigational Blood Glucose Monitoring System : Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="221"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Glucose Results From Alternative Site Testing (AST) of the Palm Within +/- 15mg/dL (&lt;75mg/dL) or Within +/- 20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
            <description>Untrained subjects with diabetes self-test Alternative Site (AST) Palm blood using an investigational Blood Glucose Monitoring System (BGMS). BGMS AST results are compared with capillary plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI capillary plasma BG results are used to calculate the number of AST BGMS results within +/- 15mg/dL (&lt;75mg/dL YSI capillary plasma) or +/- 20% (&gt;=75mg/dL YSI capillary plasma).</description>
            <units>percentage of meter test results</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>% within 15 mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 20% (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.1"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percent of Venous Blood Glucose Results Within +/- 5to15mg/dL (&lt;75mg/dL) or Within +/- 5to20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
        <description>Study staff tested subject venous blood using an investigational Blood Glucose Monitoring System (BGMS). Venous BGMS results are compared with venous plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI venous plasma results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;75mg/dL YSI venous plasma) or +/- 5to20% (&gt;=75mg/dL YSI venous plasma).</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <population>Venipuncture was unsuccessful for one subject. 223 (224-1) venous blood test results were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the G3 Investigational BG Monitoring System</title>
            <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system. Of 226 subjects enrolled, 224 completed the study.
G3 Investigational Blood Glucose Monitoring System : Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="223"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Percent of Venous Blood Glucose Results Within +/- 5to15mg/dL (&lt;75mg/dL) or Within +/- 5to20% (&gt;=75mg/dL) of Laboratory Glucose Method</title>
            <description>Study staff tested subject venous blood using an investigational Blood Glucose Monitoring System (BGMS). Venous BGMS results are compared with venous plasma BG results obtained with a Yellow Springs Instrument (YSI) Analyzer. YSI venous plasma results are used to calculate the number of BGMS results within +/- 5to15mg/dL (&lt;75mg/dL YSI venous plasma) or +/- 5to20% (&gt;=75mg/dL YSI venous plasma).</description>
            <units>percentage of meter test results</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>% within 20% (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 15% (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.5"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>%within 15 mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 12.5% (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="99.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 12.5 mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10% (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="98.6"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 10 mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="100"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5% (&gt;=75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="71.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>% within 5 mg/dL (&lt;75 mg/dL BG)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="83.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction</title>
        <description>After reading the instructions for use, and without assistance from the study staff, subjects use the BGMS to utilize some of the additional features of the system. Study staff documents Yes or No 'Did the subject complete the task successfully?'</description>
        <time_frame>1 hour</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Intended Users of the G3 Investigational BG Monitoring System</title>
            <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system. Of 226 subjects enrolled, 224 completed the study.
G3 Investigational Blood Glucose Monitoring System : Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="224"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Number of Subjects Able to Perform Given Tasks Using Product Labeling for Instruction</title>
            <description>After reading the instructions for use, and without assistance from the study staff, subjects use the BGMS to utilize some of the additional features of the system. Study staff documents Yes or No 'Did the subject complete the task successfully?'</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Mark a test result as 'Before Meal'</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="208"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Set a reminder</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="203"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Access BG trends</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="215"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Intended Users of the G3 Investigational BG Monitoring System</title>
          <description>Untrained subjects with diabetes use the G3 investigational blood glucose monitoring system. Of 226 subjects enrolled, 224 completed the study.
G3 Investigational Blood Glucose Monitoring System : Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycemia</sub_title>
                <description>Hypoglycemia events were non-serious (mild), non-device related, and anticipated.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="224"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <description>Hyperglycemic event was non-serious (mild), non-device related, and anticipated.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="224"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is more than 60 days but less than or equal to 180 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jane Wallace</name_or_title>
      <organization>Ascensia Diabetes Care</organization>
      <phone>574-257-3063</phone>
      <email>jane.wallace@ascensia.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
